


# A High-Throughput Screen for the Engineered Production of $\beta$ -Lactam Antibiotics

Ryan M. Phelan, Benjamin J. DiPardo, and Craig A. Townsend\*

Department of Chemistry, Johns Hopkins University, 3400 N. Charles Street, Baltimore, Maryland 21218, United States

**S** Supporting Information



**ABSTRACT:** High-throughput screens and selections have had profound impact on our ability to engineer proteins possessing new, desired properties. These methods are especially useful when applied to the modification of existing enzymes to create natural and unnatural products. In an advance upon existing methods we developed a high-throughput, genetically regulated screen for the *in vivo* production of  $\beta$ -lactam antibiotics using a green fluorescent protein (gfp) reporter. This assay proved reliable and sensitive and presents a dynamic range under which a wide array of  $\beta$ -lactam architectural subclasses can be detected. Moreover, the graded response elicited in this assay can be used to rank mutant activity. The utility of this development was demonstrated *in vivo* and then applied to the first experimental investigation of a putative catalytic residue in carbapenem synthase (CarC). Information gained about the mutability of this residue defines one parameter for enzymatic activity and sets boundaries for future mechanistic and engineering efforts.

$\beta$ -Lactam antibiotics are a mainstay in the treatment of bacterial infections. More than 50% of clinically used antibiotics contain a  $\beta$ -lactam core.<sup>1</sup> This class of antibiotics is structurally diverse owing to their differing biological origins. In addition to naturally occurring  $\beta$ -lactams, many of clinical relevance are produced synthetically or semisynthetically giving rise to an expanded arsenal of antibiotics.<sup>2</sup> Differentiation of the core  $\beta$ -lactam-containing ring system and variation of appendages to the bicyclic core and their oxidation state<sup>3</sup> modulate antibacterial effectiveness and stability to commonly encountered  $\beta$ -lactamase ( $\beta$ L) resistance enzymes. Inactivation of  $\beta$ -lactam antibiotics by  $\beta$ L is a problem of great concern for health care giving rise to a need for new or improved antibiotics to overcome resistance.<sup>4</sup> Recent advances in biosynthetic chemistry and metabolic engineering have proved useful in both lowering the cost and increasing the availability of complex pharmaceuticals.<sup>5–8</sup> Moreover, modification of known enzymes to create mutants with new substrate specificities has proved to be a viable tactic for producing modified natural products.<sup>9–12</sup> Generation of catalysts that can aid in synthesizing  $\beta$ -lactams with rationally altered structures would be desirable for the production of next-generation  $\beta$ -lactam antibiotics.<sup>2</sup> To this end, a reliable and high-throughput screen to identify enzymes possessing these properties, as well as potentially others such as heightened


thermostability or increased activity in organic solvents, would be particularly useful when applied to the interrogation of mutant enzyme libraries to achieve engineered  $\beta$ -lactam biosynthesis. In contrast to *in vitro*<sup>13,14</sup> or traditional growth-inhibition assays,<sup>15,16</sup> creation of a screen that is run on a single agar plate with hundreds to thousands of enzyme variants present would allow conservation of substrate while greatly increasing capacity. With this goal in mind, we aimed to design a high-throughput, highly sensitive, and reproducible screen that would function on agar plates to report the *in vivo* production of  $\beta$ -lactam antibiotics in single bacterial colonies.

In this paper we describe the development of such an assay and demonstrate its utility in a mutational investigation of a putative catalytic residue in carbapenem synthase (CarC) from *Pectobacterium carotovorum*, the terminal enzyme in the biosynthesis of the simple carbapenem 3.<sup>15,16</sup> This iron-dependent oxygenase catalyzes both coupled and uncoupled epimerization and desaturation of carbapenam 1 as shown in Figure 1. We have unambiguously established that the C-5 bridgehead hydrogen ( $H^\circ$ ) in 1 is lost during a presumed

**Received:** December 2, 2011

**Accepted:** February 14, 2012

**Published:** March 19, 2012



**Figure 1.** Epimerization and desaturation of the simple carbapenem 1 catalyzed by CarC.


radical abstraction catalyzed by the CarC iron-oxo center and replaced by another hydrogen from the opposite face of the substrate to achieve epimerization.<sup>15,16</sup> The identity of this hydrogen donor is thought to be Tyr67 based on a crystal structure of the enzyme<sup>17</sup> and molecular modeling. This proposal is backed by substrate specificity studies<sup>15,16,18</sup> and computation.<sup>19,20</sup> In the absence of experimental support for this unusual mechanism, we elected to carry out saturation mutagenesis<sup>21–23</sup> of this residue to give insight into the requirements at position 67. We therefore charged these mutants with the task of catalyzing a reaction with both its native 1 and epimerized substrate 2. Information gained about the mutability of this residue will give insight into the mechanism of CarC and aid future endeavors to expand its substrate specificity.

To create the desired *in vivo* screen, we turned to the well-studied, inducible AmpC  $\beta$ -lactamase from *Citrobacter freundii*.<sup>24,25</sup> The *C. freundii* AmpC  $\beta$ L allows for selective induction of transcription from the *ampC* promoter (*PampC*) in the presence of a  $\beta$ -lactam antibiotic. An additional benefit of the *ampC*  $\beta$ L is that it can be heterologously expressed and behaves in *E. coli* in a fashion analogous to that of *C. freundii*. Of specific importance, the *C. freundii* *ampC*  $\beta$ L has been shown to be hyperinducible when used in the *ampD* mutant *E. coli* strain SN0301.<sup>26,27</sup> AmpD is involved in recycling the cell wall fragment anhydro-muramic acid *N*-acetyl pentapeptide (anhMurNAC) that is accumulated from  $\beta$ -lactam inhibition of cell wall biosynthesis.<sup>26</sup> As a consequence, this hypersensitive strain can detect  $\beta$ -lactam antibiotics in the low nanomolar to high picomolar range, concentrations well below those that are cytotoxic to the bacterium.

*PampC* is regulated by the product of the *ampR* gene.<sup>28</sup> In the presence of the cell wall degradation product, anhMurNAC, AmpR converts from a repressor to a transcriptional activator of *ampC* (Scheme 1).<sup>24</sup> To achieve induction of fluorescence in the presence of a  $\beta$ -lactam antibiotic, we placed GFPmut2<sup>29</sup> (*gfp*) under the control of *PampC*, which was cloned with its regulatory gene, *ampR*, from pNU305.<sup>30</sup> The *gfp-PampC-ampR* gene segment was placed in the *EcoRI-PstI* fragment of pBR322 containing the tetracycline resistance marker. The sequence of the resultant plasmid, known as pRP5.199, was verified, and further tests were initiated to validate its use in the envisioned screen.

To substantiate the assay and ascertain its reliability and robustness, it was necessary to demonstrate that the fluorescent phenotype was induced in the presence of  $\beta$ -lactam antibiotics. This fluorescence response should ideally show a large induction coefficient ( $\beta$ -lactam induced colonies vs uninduced colonies) allowing for the easy identification of  $\beta$ -lactam-producing colonies. Additionally, the elicited response should be reproducible, reflected in a low coefficient of variance (CV). Use of the *PampC* system would optimally also produce a graded fluorescence response permitting differentiation among mutants of differing catalytic activities. It would be further desirable if the system were robust enough to detect a wide array of  $\beta$ -lactam structural types ranging from simple monobactams

**Scheme 1.** Induction of *gfp* by Cell-Wall Breakdown Byproducts Induced by  $\beta$ -Lactam Antibiotics



to the more highly elaborated bicyclic classes. A series of *in vitro* assays was conducted to establish the extent to which this assay met all of these criteria. The assay was then applied *in vivo* to assay for production of the simple carbapenem 3 to verify its utility and reliability *in vivo*.

To first demonstrate the range and reproducibility of the pRP5.199 assay, a series of experiments was designed in which external supplementation of  $\beta$ -lactam antibiotic was used to induce a fluorescence response. *E. coli* SN0301 containing pRP5.199 was grown overnight and replica plated on agar plates containing either 50% of the measured minimum inhibitory concentration (MIC) of a given  $\beta$ -lactam antibiotic or a control plate lacking the compound. Clear results were obtained after incubation for 16 h revealing a marked increase in fluorescence for the  $\beta$ -lactam-containing plates (Table 1). An 11- to 43-fold increase in fluorescence was observed when induced colonies were compared to their controls. The results

**Table 1.** pRP5.199 Response to  $\beta$ -Lactam Stimuli


$\beta$ -lactam	IC <sup>a</sup>	CV <sup>b</sup>
amoxicillin	32	2.1
ampicillin	21	8.5
carbenicillin	19	8.2
cefmetazole	37	9.1
clavulanic acid	11	8.5
imipenem	16	9.4
nocardicin A	15	3.7
penicillin G	43	7.3
vancomycin	1.1	9.7
phosphomycin	1.3	15.3

<sup>a</sup>Induction coefficient. <sup>b</sup>Coefficient of variance.

also demonstrated that the responses caused by these inducers were well behaved and reproducible, reflected by a CV of less than 10% for each trial. Finally, these experiments established that this assay was amenable to a wide variety of  $\beta$ -lactam architectures, exemplifying its applicability to all known classes of the  $\beta$ -lactam antibiotics.

The induction of *gfp* is triggered by cell-wall fragments (anhMurNAc) generated during  $\beta$ -lactam inhibition of cell wall biosynthesis. Since this system indirectly detects  $\beta$ -lactam antibiotics, it is important to show that it is not triggered by other cell wall synthesis inhibitors. To demonstrate specificity for  $\beta$ -lactam-induced cell wall degradation products, we incubated SN0301 containing pRP5.199 with phosphomycin or vancomycin at 50% of the MIC determined for this strain. These two well-characterized antibiotics inhibit bacterial cell wall biosynthesis, as do  $\beta$ -lactam antibiotics, but act on different stages of biosynthesis than do  $\beta$ -lactams.<sup>31,32</sup> The results of these control experiments show that neither of these bacterial cell wall inhibitors induces fluorescence above the uninduced state, inspiring confidence that this assay is specific for  $\beta$ -lactams. This result is in accord with the literature.<sup>33</sup>

Another desirable feature of any successful screen is a graded response to the input stimulus. To determine whether *PampC* exhibits such a response to  $\beta$ -lactam antibiotics, colonies of SNO301 containing pRP5.199 were grown on agar plates containing varying concentrations of amoxicillin. The results clearly demonstrated that as the concentration of  $\beta$ -lactam antibiotic increased, so did the fluorescence signal (Figure 2). The




**Figure 2.** Fluorescence response to increasing concentrations of amoxicillin.

response is non-linear, showing greater sensitivity at low concentrations when compared to changes observed as  $\beta$ -lactam concentrations approach  $\sim 50\%$  of the minimum inhibitory concentration (MIC = 1  $\mu\text{g/mL}$ ), then falling at higher concentrations as increased cellular damage occurs. One salient feature of this screening system was that amoxicillin down to the low nanomolar range (*ca.* 30 nM) elicited an approximately 500% increase in fluorescence when compared to the uninduced control. This acute sensitivity enables detection of even weakly producing mutants, especially when considering more intrinsically potent  $\beta$ -lactam antibiotics such as imipenem and related naturally occurring carbapenem antibiotics.


To validate this assay for *in vivo* production of antibiotic, we turned to a well-characterized biosynthetic pathway, that of the simple carbapenem **3**, to use as a model system. In particular, we focused on the enzyme CarC, which catalyzes the unusual bridgehead epimerization and desaturation of the antibiologically inactive (3*S*,5*S*)-carbapenem **1** to the active (5*R*)-carbapenem **3**, with (3*S*,5*R*)-carbapenem **2** as a freely diffusible intermediate.<sup>15,16</sup> Initial evaluation focused on the direct comparison of two *E. coli* strains that either possessed or lacked the ability to catalyze the reaction of **2** to **3**. Expression of CarC in *E. coli* SN0301 was achieved by placing a codon-optimized variant of CarC, CarCopt, under control of the *tac* promoter contained in the expression vector pDIMC8K (see Supporting Information). *E. coli* SN0301 was transformed with pDIMC8K-CarCopt or the control vector, pDIMC8K-MalE (*malE* codes for the maltose-binding protein, which has no effect on the assay and was used in control reactions) in conjunction with pRP5.199. These strains were grown overnight and replica plated on bioassay plates containing the appropriate antibiotics,  $\text{Fe}^{2+}$ , IPTG, and **2**. Bioassay plates were incubated at 37 °C for 16 h and then scanned for fluorescence using a phosphor-imager. A dramatic response was observed in which the cell line possessing the ability to catalyze the formation of the active antibiotic **3** showed a 45-fold increase in fluorescence as compared to the control cell line (Supporting Information, Table S1). This result was encouraging in several ways. Not only did *in vivo* production of the antibiotic occur on the agar plate, but it elicited a fluorescence response that rivaled the best of the *in vitro* experiments. To solidify this assay as a reliable tool for the identification and ranking of  $\beta$ -lactam-producing colonies, *in vivo* comparison of three *E. coli* strains that either possessed to varying degrees or lacked entirely the ability to catalyze the reaction of **1** to **3** was executed. Two cell lines harbored either CarCopt (*E. coli* RP1) or wild-type (wt) CarC (*E. coli* RP2), in addition to pRP5.199. Owing to the greater *in vivo* production of CarC by the optimized gene *vs* wt, the reaction is catalyzed in a more efficient manner, which translates into a greater fluorescence signal for the CarCopt-bearing cell line. Additionally, a control cell line absent the ability to catalyze the reaction, pDIMC8K-MalE (*E. coli* RP3) containing pRP5.199, was generated (*E. coli* RP3). It was expected that all three cell lines would show differing fluorescence intensities (RP1 > RP2 > RP3) and that these cells could be differentiated and separated using this assay. To test this hypothesis, these strains were combined in an approximately 1:1:8 (RP1:2:3) ratio, grown overnight, and replica plated on bioassay plates as previously described. Evaluation of the plates showed three cell lines exhibiting different fluorescence intensities (Figure 3; Supporting Information, Table S2). Members of groups exhibiting high, medium, and low fluorescence intensities were grouped, and their sequences were verified. The results showed, as expected, that cell lines could be distinguished using this assay with no crossover of the RP1, 2, or 3 cell lines into an incorrect fluorescence intensity group. With this mock screen verifying the capabilities of this assay to not only distinguish  $\beta$ -lactam producers from non-producers but also allow ranking of catalytically superior to inferior cell lines, we sought to use this assay to address a central question about the catalytic mechanism of CarC.

CarC is a unique bifunctional member of the nonheme iron  $\alpha$ -ketoglutarate dependent oxygenase family that has been proposed to catalyze the C5 epimerization of **1** producing **2** by way of iron–oxygen catalyzed radical abstraction and hydrogen



**Figure 3.** Image of fluorescence intensities of *E. coli* RP1, 2, and 3. Intensity ranges from weak fluorescence (blue), medium (orange), and strong (red). Dark blue indicates no activity continuing to bright red, which indicates wild-type activity.

donation from the opposite face.<sup>15–20</sup> A model depicting the likely positioning of (3*S*,5*S*)-carbapenam **1** in the CarC crystal structure was generated *in silico* and revealed that a small movement of less than 2.5 Å by the Tyr67 β-carbon, followed by rotation around the α,β-carbon bond would position Tyr67 for hydrogen donation to C5, resulting in bridgehead epimerization (Figure 4). Since efforts to redesign the substrate



**Figure 4.** Depiction of how (3*S*,5*S*)-carbapenam may reside in the active site with the C5 hydrogen poised for abstraction by the iron-oxo (orange) center followed by replacement of the hydrogen by Y67 leading to C5 inversion.

specificity of CarC require biochemical understanding of its mechanism, that is whether or not Tyr67 is essential for catalysis, we chose to address the proposed role of Tyr67 in both the full-reaction (**1** → **3**) and the second half-reaction (**2** → **3**). To investigate the residue requirements for position 67, we performed saturation mutagenesis<sup>21–23</sup> at this locus in wild-type CarC and screened the point mutants against both **1** and **2**. Screening of all amino acid variants with **1** found that Tyr was the only amino acid tolerated at this site that could

carry out the full reaction. Although this observation does not strictly prove the involvement of Tyr67 in the reaction as a radical shuttle, it is the first experimental evidence to support the participation of this residue in catalysis. Results for the second-half reaction were expected to differ, as C5 epimerization had already occurred, and, therefore, a hydrogen donor (tyrosine) would no longer be necessary for catalysis. Interestingly, a limited set of highly similar amino acids, Tyr67, Y67F and Y67W, was required to sustain the reaction with the latter two mutants possessing reduced catalytic efficiency (*ca.* 30% of wt; Supporting Information, Tables S3 and S4). Combined, these results reveal the necessity of Tyr67 for substrate epimerization, but not desaturation, and demonstrate the requirement for an aromatic residue at position 67, even for the simple desaturation reaction.

Reported here is the first high-throughput assay for the *in vivo* production of β-lactam antibiotics. This assay was shown to be reliable and reproducible as demonstrated by the low CV exhibited in both the *in vivo* and *in vitro* experiments. Owing to the fact that the assay indirectly detects β-lactam antibiotics by the production of unique β-lactam-induced cell wall degradation products (anhMurNAc), the assay is specific to β-lactam antibiotics, but general to all known structural classes. This assay shows a good dynamic range across these diverse structural types represented by an 11- to 45-fold increase in detected fluorescence, with the *in vivo* synthesis of the simple carbapenam **3** displaying the largest fluorescence increase. The graded response offers a means to discern highly active from less active mutants, improving the screening process to rapidly identify the most active clone(s). Of further importance, the ability of this assay to sensitively operate in the nanomolar range enables identification of even weakly producing mutants that can be carried on to additional rounds of mutagenesis to potentially enhance activity. In a test of the assay, it was applied to probe the amino acid requirement at position 67 in CarC, proposed to serve as a key radical shuttle in the overall catalytic cycle of the enzyme. This experiment, the first biochemical investigation of residue requirements in the active site of CarC, supports hypotheses advanced to account for the unusual bifunctional reaction catalyzed by this enzyme. The strict tolerance observed for aromatic residues at this site defines one important parameter for future engineering of this enzyme, and taken together these experiments demonstrate an assay superior to current methods for identification of β-lactam production with greater reliability, conservation of substrate, and high throughput.

## METHODS

***In Vitro* Assay for Detection of β-Lactam Antibiotics.** *E. coli* SN0301 containing pRP5.199 was grown overnight at 37 °C on 2xYT (1.5% agar) containing 1.0% glycerol, tetracycline (5 μg/mL), and kanamycin (25 μg/mL). The cells were grown until colonies were visible and then replica plated on LB agar (1.5% agar) containing 1% glycerol, tetracycline (5 μg/mL), and kanamycin (25 μg/mL) in addition to the appropriate β-lactam antibiotic at 50% of the determined MIC or no β-lactam, which served as the control plate. The replica plates were grown 16 h at 37 °C. Plate analysis was performed on a Typhoon 9410 phosphorimager (GE Healthcare, Piscataway, NJ) using 300 V excitation with a 488 nm laser and a 526 short-pass cutoff filter with 100 μm resolution and +3 mm top focusing. All images were quantitated using Image Quant TL (GE Healthcare).

***In Vivo* Assay for Detection of β-Lactam Production.** *E. coli* SN0301 containing pRP5.199 the desired pDIMC8K vector (pDIMC8K-CarCopt, pDIMC8K-CarAC or pDIMC8K-MaIE at a

1:1:8 ratio (RP1:2:3) for separation trials or pDIMC8K-CarCY67X for saturation mutagenesis experiments) was grown overnight at 37 °C on 2xYT (1.5% agar) containing 1.0% glycerol, tetracycline (5 µg/mL), and kanamycin (25 µg/mL). The cells were grown 18 h and replica plated on LB agar (1.5% agar) containing ferrous ammonium sulfate (80 µM), IPTG (1 mM), tetracycline (5 µg/mL), kanamycin (25 µg/mL), and (3S,5S)-carbapenam (1, 500 µM) or (3S,5R)-carbapenam (2, 250 µM for initial *in vivo* trials or 200 µM for separation trials). The replica plates were grown for 16 h at 37 °C. Plate analysis was performed on a Typhoon 9410 phosphorimager (GE Healthcare, Piscataway, NJ) using 300 V excitation with a 488 nm laser and a 526 short-pass cutoff filter with 100 µm resolution and +3 mm top focusing. All images were quantitated using Image Quant TL (GE Healthcare). The Y67X point mutants were screened against 1 and 2 with >95% confidence that all codons were present.

**Quantitative Analysis of pRP5.199 Trial Assay.** After fluorescence was read, the data were analyzed using ImageQuant TL (GE Lifesciences). Each colony was interrogated separately using a correction for background fluorescence. Arbitrary fluorescence units were recorded for each colony. The average of the control cell line (*E. coli* SN0301-pDIMC8K-MalE/pRP5.199) was used to determine fluorescence intensity attributed to the basal transcription of *gfp* from pRP5.199. Normalized data are the raw fluorescence less the background fluorescence.

**Computational Modeling of (3S,5S)-Carbapenam in the CarC Active Site.** All computational work was performed using Discovery Studio 2.1. The carbapenam was created using the Discovery Studio drawing function and energy minimized using the Smart Minimizer program. The substrate was manually docked in the CarC (PDB ID: 1NX8) B-subunit active site and constraints were set so that the iron-oxo center would be within 2.75–3.25 Å of the carbapenam C5 and a further constraint was to set the tyrosyl hydroxyl at 2.75–3.25 Å. The system was typed with the 3 CHARMM<sup>33</sup> algorithm and minimized using an adopted basis NR algorithm with a generalized Born implicit solvent model with molecular volume. The resultant minimized model was visualized using PyMol.

## ■ ASSOCIATED CONTENT

### ● Supporting Information

This information is available free of charge *via* the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

### Corresponding Author

\*E-mail: [ctownsend@jhu.edu](mailto:ctownsend@jhu.edu).

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

We are grateful to R.-F. Li for pET24b-CarAC and continuing discussions, A. Stapon and K. A. Moshos for early mechanistic insights, A. R. Buller for help with computer graphics, M. Ostermeier and R. A. Heins for pDIMC8-MalE and pDB2-GFP and for their guidance, S. Lindquist (University of Umea) for pNU305, and the National Institutes of Health for financial support (AI014937).

## ■ REFERENCES

- (1) Demain, A. L., and Sanchez, S. (2009) Microbial drug discovery: 80 years of progress. *J. Antibiot.* 62, 5–16.
- (2) Anderson, I., Terwisscha van Scheltinga, A. C., and Valegard, K. (2001) Towards new  $\beta$ -lactam antibiotics. *Cell. Mol. Life Sci.* 58, 1897–1906.
- (3) Bodner, M. J., Phelan, R. M., Freeman, M. F., Li, R., and Townsend, C. A. (2010) Non-heme iron oxygenases generate natural structural diversity in carbapenam antibiotics. *J. Am. Chem. Soc.* 132, 12–13.

- (4) Fisher, J. F., Meroueh, S. O., and Mobashery, S. (2005) Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. *Chem. Rev.* 105, 395–424.

- (5) Ro, D., Paradise, E. M., Ouellet, M., Fisher, K. J., Newman, K. L., Ndungu, J. M., Ho, K. A., Eachus, R. A., Ham, T. S., Kirby, J., Chang, M. C. Y., Withers, M. C. Y., Shiba, Y., Sarpong, R., and Keasling, J. D. (2006) Production of the antimalarial drug precursor artemisinic acid in engineered yeast. *Nature* 440, 940–943.

- (6) Guo, J., and Frost, J. W. (2004) Synthesis of 5-amino-5-deoxyshikimate. *Org. Lett.* 6, 1585–1588.

- (7) Dietrich, J. A., Yoshikuni, Y., Fisher, K. J., Woolard, F. X., Ockey, D., McPhee, D. J., Renninger, N. S., Yang, M. C. Y., Baker, D., and Keasling, J. D. (2009) A novel semi-biosynthetic route for artemisinin production using engineered substrate-promiscuous P450BM3. *ACS Chem. Bio.* 4, 261–267.

- (8) Li, S., Chaulagain, M. J., Knauff, A. R., Podust, L. M., Montgomery, J., and Sherman, D. H. (2009) Selective oxidation of carbolide C–H bonds by an engineered macrolide P450 monooxygenase. *Proc. Natl. Acad. Sci. U.S.A.* 106, 18463–18468.

- (9) Marsden, A. F. A., Wilkenson, B., Cortes, J., Dunstner, N. J., Staunton, J., and Leadley, P. F. (1998) Engineering broader specificity into an antibiotic-producing polyketide synthase. *Science* 279, 199–202.

- (10) Weissman, K. J., and Leadley, P. F. (2005) Combinatorial biosynthesis of reduced polyketides. *Nat. Rev. Microbiol.* 3, 923–938.

- (11) Runguphan, W., and O'Connor, S. E. (2009) Metabolic reprogramming of periwinkle plant culture. *Nat. Chem. Biol.* 5, 151–153.

- (12) Runguphan, W., Qu, X., and O'Connor, S. E. (2010) Integrating carbon-halogen bond formation into medicinal plant metabolism. *Nature* 468, 461–467.

- (13) Chan, H., Liu, H., Chen, Y., Chan, K., Tsang, C., Leung, Y., and Wong, K. (2004) Rational design of a novel fluorescent biosensor for  $\beta$ -lactam antibiotics from a class A  $\beta$ -lactamase. *J. Am. Chem. Soc.* 126, 4074–4075.

- (14) Valtonen, S. J., Kurittu, J. S., and Karp, M., T. (2002) A luminescent *Escherichia coli* biosensor for the high throughput detection of  $\beta$ -lactams. *J. Biomol. Screen.* 7, 127–134.

- (15) Stapon, A., Li, R., and Townsend, C. A. (2003) Carbapenam biosynthesis: Confirmation of stereochemical assignments and the role of CarC in the ring stereoinversion process from L-proline. *J. Am. Chem. Soc.* 125, 8486–8493.

- (16) Stapon, A., Li, R., and Townsend, C. A. (2003) Synthesis of (3S,5R)-carbapenam-3-carboxylic acid and its role in carbapenam biosynthesis and the stereoinversion problem. *J. Am. Chem. Soc.* 125, 15746–15747.

- (17) Clifton, I. J., Doan, L. X., Sleeman, M. C., Topf, M., Suzuki, H., Wilmouth, R. C., and Schofield, C. J. (2003) The crystal structure of carbapenam synthase (CarC). *J. Biol. Chem.* 278, 20843–20850.

- (18) Sleeman, M. C., Smith, P., Kellam, B., Chhabra, S., Bycroft, B. W., and Schofield, C. J. (2004) Biosynthesis of carbapenam antibiotics: new carbapenam substrates for carbapenam synthase (CarC). *ChemBioChem* 5, 879–882.

- (19) Topf, M., Sandala, G. M., Smith, D. M., Schofield, C. J., Easton, C. J., and Radom, L. (2004) The unusual bifunctional catalysis of epimerization and desaturation by carbapenam synthase. *J. Am. Chem. Soc.* 126, 9932–9933.

- (20) Borowski, T., Broclawik, E., Schofield, C. J., and Siegbahn, P. E. M. (2006) Epimerization and desaturation by carbapenam synthase (CarC). A hybrid DFT study. *J. Comput. Chem.* 27, 740–748.

- (21) Kast, P., Asif-Ullah, M., Jiang, N., and Hilvert, D. (1996) Exploring the active site of chorismate mutase by combinatorial mutagenesis and selection: the importance of electrostatic catalysis. *Proc. Natl. Acad. Sci. U.S.A.* 93, 5043–5048.

- (22) Künzler, D. E., Sasso, S., Gamper, M., Hilvert, D., and Kast, P. (2005) Mechanistic insights into the isochorismate pyruvate lyase activity of the catalytically promiscuous PchB from combinatorial mutagenesis and selection. *J. Biol. Chem.* 280, 32827–32834.

(23) Wilming, M., Iffland, A., Tafelmeyer, P., Arrivoli, C., Saudan, C., and Johnsson, K. (2002) Examining reactivity and specificity of cytochrome *c* peroxidase by using combinatorial mutagenesis. *ChemBioChem* 3, 1079–1104.

(24) Jacobs, C., Frere, J., and Normark, S. (1997) Cytosolic intermediates for cell wall biosynthesis and degradation control inducible beta-lactam resistance in Gram-negative bacteria. *Cell* 88, 823–832.

(25) Sohka, T., Heins, R. A., Phelan, R. M., Greisler, J. M., Townsend, C. A., and Ostermeier, M. (2009) An externally tunable bacterial band-pass filter. *Proc. Natl. Acad. Sci. U.S.A.* 106, 10135–10140.

(26) Lindquist, S., Galleni, M., Lindberg, F., and Normark, S. (1989) Signaling proteins in enterobacterial AmpC  $\beta$ -lactamase regulation. *Mol. Microbiol.* 3, 1091–1102.

(27) Bennett, P. M., and Chopra, I. (1993) Molecular basis of beta-lactamase induction in bacteria. *Antimicrob. Agents Chemother.* 37, 153–158.

(28) Bartowsky, E., and Normark, S. (1993) Interactions of wild-type and mutant AmpR of *Citrobacter freundii* with target DNA. *Mol. Microbiol.* 10, 555–566.

(29) Cormack, B. P., Valdivia, R. H., and Falkow, S. (1996) FACS-optimized mutants of the green fluorescent protein (GFP). *Gene* 173, 33–38.

(30) Lindberg, F., Lindquist, S., and Normark, S. (1987) Inactivation of the *ampD* gene causes semiconstitutive overproduction of the inducible *Citrobacter freundii* beta-lactamase. *J. Bacteriol.* 169, 1923–1928.

(31) Patel, S. S., Balfour, J. A., and Bryson, H. M. (1997) Fosfomycin tromethamine: A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. *Drugs* 53, 637–656.

(32) Bugg, T. D. H., Wright, G. D., Dutka-Malen, S., Arthur, M., Courvalin, P., and Walsh, C. T. (1991) Molecular basis for vancomycin resistance in *Enterococcus faecium* BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. *Biochemistry* 30, 10408–10415.

(33) Dietz, H., Pfiel, D., and Wiedemnn, B. (1997) The signal molecule for beta-lactamase induction in *Enterobacter cloacae* is the anhydromuramyl-pentapeptide. *Antimicrob. Agents Chemother.* 41, 2113–2120.

(34) Brooks, B. R., Brucoleri, R. E., Olafson, B. D., States, D. J., Swaminathan, S., and Karplus, M. (1983) CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. *J. Comput. Chem.* 4, 187–217.